Clinical Trial Search

Phase 3 N=833 Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Kidney Transplantation · Graft Rejection

Primary: Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis — 75; 60; 70; 8 Participants

Novartis Results May 2011 65.1% serious AE View details

Phase 3 N=460 Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Hypertension · Left Ventricular Hypertrophy · Overweight

Primary: Change in Left Ventricular Mass Index (LVMI) From Baseline to End of Study (Week 36) — -5.51; -4.81; -5.61 g/m^2

Novartis Pharmaceuticals Results May 2011 7.2% serious AE View details

Phase 3 N=366 Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

Stomach Ulcer · Duodenal Ulcer

Primary: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer — 15; 46 participants — p=<0.0001

Takeda Results May 2011 12.6% serious AE View details

Phase 3 N=601 A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Hypertension

Primary: Overall Percentage of Patients With Adverse Events — 76.2 percentage of patients

Novartis Results May 2011 2.4% serious AE View details

Phase 3 N=865 Migraine Study in Adolescent Patients

Migraine Disorders

Primary: Number of Participants Who Were Pain Free at 2 Hours Post-dose — 14; 28; 26; 36 participants — p=0.003

GlaxoSmithKline Results May 2011 0.2% serious AE View details

Phase 3 N=883 BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

HIV Infections

Primary: Number of Participants With Human-immunodeficiency Virus- Ribonucleic Acid (HIV-RNA) < 50 Copies (c)/mL at Week 48 — 343; 338 Participants

Bristol-Myers Squibb Results May 2011 12.4% serious AE View details

Phase 3 N=74 Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6) — -8.3; -10.3; -14.4 mm Hg — p=0.0990

Novartis Pharmaceuticals Results May 2011 5.4% serious AE View details

Phase 3 N=720 Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Pneumococcal Vaccines

Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0) — 148; 148; 125; 80 geometric mean titer

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 1.5% serious AE View details

Phase 3 N=168 Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy

Pancreatic Fistula

Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants

Seoul National University Hospital Results May 2011 0.0% serious AE View details

Phase 3 N=1,191 Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Hypertension

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg

Novartis Results May 2011 1.1% serious AE View details

Phase 3 N=1,063 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Primary: American College of Rheumatology 20% (ACR20) Response at Week 12 — 51.1; 25.9 percentage of subjects

UCB Pharma Results May 2011 7.0% serious AE View details

Phase 3 N=682 Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Major Depressive Disorder

Primary: Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET) — -8.42; -9.28; -8.92 Units on a scale — p=0.175

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 0.7% serious AE View details

Phase 3 N=150 Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Primary: Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Intent-to-Treat (ITT) Population — 0.97; 1.01 Units on a scale

Novartis Results May 2011 0.0% serious AE View details

Phase 3 N=300 Study of Oral Fampridine-SR in Multiple Sclerosis

Multiple Sclerosis

Primary: Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk) — 6; 78 Participants

Acorda Therapeutics Results May 2011 5.3% serious AE View details

Phase 3 N=819 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Primary: SLE Responder Index (SRI) Response Rate at Week 52 — 33.5; 40.6; 43.2 Percentage of participants — p=0.0167

Human Genome Sciences Inc. Results May 2011 21.7% serious AE View details